{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:51:58Z","timestamp":1765486318857,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.coviro.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T17:36:16Z","timestamp":1564162576000},"page":"84-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Assessment of antiviral therapeutics in animal models of Lassa fever"],"prefix":"10.1016","volume":"37","author":[{"given":"Bryce M","family":"Warner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinayakumar","family":"Siragam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek R","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.06.010_bib0005","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.359.6381.1201","article-title":"Nigeria hit by unprecedented Lassa fever outbreak","volume":"359","author":"Roberts","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0010","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018","volume":"379","author":"Siddle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.06.010_bib0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","article-title":"Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice","volume":"311","author":"Fisher-Hoch","year":"1995","journal-title":"BMJ"},{"unstructured":"An update of Lassa fever outbreak in Nigeria for Week 52. Nigeria Centre for Disease Control, (December 2018).","key":"10.1016\/j.coviro.2019.06.010_bib0020"},{"unstructured":"An update of Lassa fever outbreak in Nigeria for Week 13. Nigeria Centre for Disease Control, (March 2019).","key":"10.1016\/j.coviro.2019.06.010_bib0025"},{"key":"10.1016\/j.coviro.2019.06.010_bib0030","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"Muller","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.coviro.2019.06.010_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0092-8674(00)81289-1","article-title":"Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease","volume":"84","author":"Durbin","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.06.010_bib0040","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JVI.06284-11","article-title":"Functional interferon system is required for clearance of Lassa virus","volume":"86","author":"Yun","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.06.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005656","article-title":"Chimeric mice with competent hematopoietic immunity reproduce key features of severe Lassa fever","volume":"12","author":"Oestereich","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.06.010_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072290","article-title":"Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers","volume":"8","author":"Rieger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.06.010_bib0055","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1128\/JVI.01433-13","article-title":"Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus","volume":"87","author":"Yun","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.06.010_bib0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","article-title":"Pathogenesis of Lassa virus infection in guinea pigs","volume":"37","author":"Jahrling","year":"1982","journal-title":"Infect Immun"},{"key":"10.1016\/j.coviro.2019.06.010_bib0065","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/v4102031","article-title":"Pathogenesis of Lassa fever","volume":"4","author":"Yun","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0070","doi-asserted-by":"crossref","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2019.06.010_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0104-x","article-title":"A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs","volume":"4","author":"Stein","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coviro.2019.06.010_bib0080","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/infdis\/jit004","article-title":"A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques","volume":"207","author":"Safronetz","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_bib0085","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-8-205","article-title":"Pathogenesis of Lassa fever in cynomolgus macaques","volume":"8","author":"Hensley","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2019.06.010_bib0090","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4269\/ajtmh.1982.31.1038","article-title":"Pathology of Lassa virus infection in the rhesus monkey","volume":"31","author":"Callis","year":"1982","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.06.010_bib0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","article-title":"Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin","volume":"141","author":"Jahrling","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.06.010_bib0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","article-title":"Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys","volume":"149","author":"Jahrling","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_bib0115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of Favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_bib0120","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_bib0125","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_bib0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0135","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to treat Lassa virus infection in macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2019.06.010_bib0140","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1128\/JVI.00941-08","article-title":"Identification of a broad-spectrum arenavirus entry inhibitor","volume":"82","author":"Larson","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.06.010_bib0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","article-title":"Evaluation of Lassa antiviral compound ST-193 in a guinea pig model","volume":"90","author":"Cashman","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2019.06.010_bib0150","doi-asserted-by":"crossref","first-page":"18734","DOI":"10.1074\/jbc.M802089200","article-title":"Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses","volume":"283","author":"Lee","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2019.06.010_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007439","article-title":"A potent Lassa virus antiviral targets an arenavirus virulence determinant","volume":"14","author":"Madu","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.06.010_bib0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02185-18","article-title":"Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses","volume":"93","author":"Hulseberg","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.06.010_bib0165","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"PREVAIL II Writing Group","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.06.010_bib0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jmv.1890120203","article-title":"Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin","volume":"12","author":"Jahrling","year":"1983","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2019.06.010_bib0175","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","article-title":"Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization","volume":"79","author":"Jahrling","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.06.010_bib0180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies","volume":"133","author":"Cross","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2019.06.010_sbref0190","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.06.010_bib0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:01:57Z","timestamp":1761818517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":39,"alternative-id":["S1879625719300458"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.06.010","relation":{},"ISSN":["1879-6257"],"issn-type":[{"type":"print","value":"1879-6257"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of antiviral therapeutics in animal models of Lassa fever","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}